Related Experiment Videos
Calcium channel blockers in congestive heart failure: theoretic considerations and clinical experience
Insights
Calcium channel blockers can treat congestive heart failure by improving cardiac output. Nifedipine shows benefits in heart failure patients, while verapamil and diltiazem have limited data and potential risks.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Calcium channel blockers (CCBs) are explored for treating congestive heart failure (CHF).
- CCBs vary in their effects on vasculature, myocardial contractility (inotropy), and heart rate (chronotropy).
- Potential for negative inotropic effects necessitates careful selection of CCBs in heart failure management.
Purpose of the Study:
- To evaluate the efficacy and safety of different calcium channel blockers in patients with congestive heart failure.
- To compare the hemodynamic effects of nifedipine, verapamil, and diltiazem in heart failure.
Main Methods:
- Review of clinical data and patient experiences with CCBs in heart failure.
- Analysis of hemodynamic responses, including cardiac index and left ventricular filling pressure.
- Assessment of effects on systemic vascular resistance and venous pressures.
Main Results:
- Nifedipine demonstrated significant improvements in cardiac index (+24%) and reduced left ventricular filling pressure (-15%) in over 100 heart failure patients.
- Nifedipine primarily reduces afterload by affecting arteriolar resistance vessels with minimal impact on venous pressures.
- Limited data suggest nifedipine's benefits are sustained with long-term therapy.
Conclusions:
- Nifedipine appears to be a beneficial vasodilator for patients with moderate to severe congestive heart failure.
- Verapamil may cause decompensation in severe left ventricular dysfunction due to its negative inotropic effects.
- Diltiazem's limited negative inotropic action may allow its safe use in heart failure, especially when managing supraventricular tachyarrhythmias.
Abstract:
Although it has been suggested that calcium channel blocking agents may be utilized as vasodilators in patients with congestive heart failure, these agents also have the potential to cause a deterioration in cardiac function because of their negative inotropic actions. There is considerable variation among the available agents with regard to their relative effects on the vasculature, myocardial inotropy, and myocardial chronotropy. Thus, at clinically relevant dosages, nifedipine is a potent systemic and coronary vasodilator, but it has little or no direct effect on inotropy and chronotropy. In contrast, verapamil exerts significant negative inotropic and chronotropic effects at vasodilatory dosages, whereas diltiazem is a potent vasodilator with a negative chronotropic action at dosages that do not affect inotropy. In patients with heart failure, the largest experience so far has been with nifedipine. Data derived from over 100 patients with moderate to severe congestive heart failure indicate a generally beneficial net hemodynamic response to nifedipine, with substantial improvements in cardiac index (+24 percent) and left ventricular filling pressure (-15 percent). The major effect seems to be on arteriolar resistance vessels, resulting in a reduction in afterload, with relatively little effect on venous pressures. Limited data suggest that the initial effect is sustained during long-term therapy. The clinical experience with verapamil and diltiazem in patients with heart failure is at present limited. In patients with normal or mildly impaired left ventricular function, verapamil's vasodilator and negative inotropic effects are counterbalanced. With severe left ventricular dysfunction, however, treatment with verapamil can result in abrupt decompensation and development of overt pulmonary edema and hypotension. Diltiazem's relative lack of negative inotropic effects may allow it to be used safely in patients with congestive heart failure, particularly when control of supraventricular tachyarrhythmia is required.